Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial.

Gadgeel, Shirish M.Dols, Manuel CoboFelip, EnriquetaSoria, Jean-CharlesLee, Ki HyeongLu, ShunGeorgoulias, VassilisFulop, AndreaGoker, ErdemSyrigos, Konstantinos N.Morabito, AlessandroCoskun, Hasan SenolGuclu, Salih ZekiLi, WeiPopat, SanjayArdizzoni, AndreaLungershausen, JulianeWang, BushiChand, Vikram K.Goss, Glenwood D.2019-10-272019-10-2720150732-183X1527-7755https://hdl.handle.net/11454/50495Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer -- MAY 29-JUN 02, 2015 -- Chicago, ILeninfo:eu-repo/semantics/closedAccessAfatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial.Conference Object3315WOS:000358036901812Q1